TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is viewed positively because its liquid tumor program continues to show encouraging clinical signal, with all 13 Cohort C patients achieving complete donor chimerism as of August 27th and a ~20% relapse rate at 6 months comparing favorably with historical post-HSCT relapse rates. Cost-saving actions, including a ~75% reduction in force and about $55M in cumulative savings through YE:27, help extend the company’s $100M 2Q:26 cash position into 4Q:27, though additional capital is still needed to reach key milestones. The longer-dated solid tumor pipeline also adds upside, with PRAME and MAGE-A4 programs in IND-enabling studies and major readouts expected in 1Q:27, 3Q:27, 4Q:27, and initial Phase I data in 2028.

TScan Therapeutics is facing a deteriorating fundamental profile because it is pausing its most advanced hematology asset, TSC-101, by halting ALLOHA-2 enrollment due to insufficient capital, which removes a key near-term value driver and forces reliance on a strategic partner for further development. The company is also pivoting almost entirely to preclinical in vivo TCR-T programs targeting PRAME and MAGE-A4, but first preclinical data are not expected until 1Q27 and the first IND until 3Q27, leaving a long period with no validated clinical catalyst. Although restructuring is expected to generate about $55M of savings and extend runway into 4Q27, the 75% workforce cut, elimination of internal manufacturing, and dependence on additional financing or partnering underscore substantial execution, financing, and development risk.